OKYO Pharma Ltd Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on July 22, 2026. The report discloses a voluntary purchase of company stock by an executive officer rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific transaction: the purchase of 20,000 ordinary shares at $1.40 per share.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The significant event is the insider transaction by the Chief Medical Officer.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports the share purchase by Flavio Mantelli, MD, PhD, Chief Medical Officer, executed on the NASDAQ.
Key Facts for Investor Verification
- Insider Transaction: CMO Flavio Mantelli purchased 20,000 shares.
- Transaction Price: $1.40 per share.
- Transaction Date: July 22, 2026.
- Market: NASDAQ.
- Financial Data: No financial statements or metrics are included in this specific filing.